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Abstract Loss-of-function mutations in the gene WISP3
cause the autosomal recessive human skeletal disease
Progressive Pseudorheumatoid Dysplasia, whereas mice
with knockout mutations of Wisp3 have no phenotype.
The lack of a phenotype in the Wisp3 knockout mice has
constrained studies of the protein’s in vivo function. Over-
expression experiments in zebrafish indicated that WISP3
may function as a BMP and Wnt signaling modulator. To
determine whether these biologic activities are retained in
mice, we created two strains of transgenic mice that over-
express WISP3 in a broad array of tissues. Despite strong
and persistent protein over-expression, the transgenic mice
remained phenotypically indistinguishable from their non-
transgenic littermates. Surprisingly, WISP3 contained in
conditioned medium recovered from transgenic mouse
primary kidney cell cultures was able to bind BMP and to
inhibit BMP signaling in vitro. Factors that account for the
difference between the in vitro and in vivo activities of
WISP3 remain unknown. At present, the mouse remains a
challenging model organism in which to explore the
biologic function of WISP3.
Summary of article. Transgenic mice that broadly over-
express WISP3 were created to search for in vivo biologic
activities, since mice that lack WISP3 were normal.
Surprisingly, transgenic mice were also phenotypically
indistinguishable from wild-type animals. The mouse is a
challenging model organism in which to explore the
biologic function of WISP3.
Keywords WISP3.CCN.BMP.Wnt
Introduction
Mutations in the secreted protein Wnt-1 inducible signaling
pathway protein 3 (WISP3) cause the autosomal recessive,
human, skeletal disease, Progressive Pseudorheumatoid
Dysplasia (PPD) (Hurvitz et al. 1999). Individuals with
PPD appear normal at birth, develop clinical symptoms
between 3 and 8 years-of-age, and progress to severe
degenerative joint disease requiring joint replacement
surgery by their second decade of life (Wynne-Davies et
al. 1982; Spranger et al. 1983; el-Shanti et al. 1997; Sewairi
and Warman 2003). Individuals with PPD have no organ
involvement outside of their skeletal system. Consequently,
in humans, the principal role of WISP3 appears to involve
skeletal growth and cartilage homeostasis.
Given the cartilage phenotype in patients with PPD, in vitro
studies using primary human chondrocytes or chondrocyte
cell lines have been performed to precisely define the biologic
function of WISP3. Over-expression of human WISP3
(hWISP3) in human chondrocyte cell lines was reported to
increase expression of type II collagen, aggrecan, and Sox9,
as determined by semi-quantitative reverse transcription
polymerase chain reaction (RT-PCR) and/or by Western blot
(Sen et al. 2004). Human primary chondrocytes recovered
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surgery were noted to have increased cell proliferation and
abnormalmatrixmetalloproteinaseprocessingwhencompared
to wild-type chondrocytes from a single control (Zhou et al.
2007). However, the in vivo relevance for either of these
findings has not been determined. The ease of manipulating
WISP3 expression in zebrafish by injecting morpholinos and
mRNA into fertilized eggs allowed us to employ knock-
down and over-expression approaches to explore in vivo
actions of zebrafish WISP3 (zWISP3) (Nakamura et al.
2007). These studies indicated that zWISP3 was capable of
modulating canonical BMP and Wnt signaling in developing
zebrafish (Nakamura et al. 2007).
WISP3 is a member of the CCN protein family.
Mammalian CCN family members have been implicated
in a broad array of biologic processes (Chen and Lau 2008)
and are characterized by shared conserved structural
domains (Rachfal and Brigstock 2005; Leask and Abraham
2006). One of these domains, a carboxy-terminal cystine
knot, is also found in several known BMP and Wnt
signaling modulators such as Noggin, SOST, and WISE,
as well as in members of the TGF-β superfamily (Piccolo et
al. 1999; Brunkow et al. 2001; Brigstock 2003; Itasaki et al.
2003; Avsian-Kretchmer and Hsueh 2004; Perbal 2004).
Consequently, the function of WISP3 in mammalian cartilage
could be to fine tune BMP and Wnt signaling. Complicating
the in vivo study of WISP3 function in humans and mice is
that, in our hands, it’s expression is detectable only by RT-
PCR, and not by in situ hybridization or immunohistochem-
istry (Kutz et al. 2005). Furthermore, a targeted knockout
mutation in mouse Wisp3 (mWisp3) caused no detectable
phenotype (Kutz et al. 2005). One potential explanation for
this finding is functional redundancy in mice between
WISP3 and other CCN family members or BMP and Wnt
regulators. Therefore, we created transgenic mice that
broadly over-express WISP3 to determine whether an in
vivo biologic activity could be identified.
Here we report that WISP3 over-expressing mice are
viable, fertile, and phenotypically indistinguishable from
their non-transgenic littermates. This result is surprising
since the WISP3 protein expressed by primary kidney cell
cultures from the transgenic mice retained the ability to bind
BMP and to inhibit BMP signaling in vitro. We conclude
that delineating the in vivo roles of WISP3 in mammals
may not be possible unless factors responsible for differ-
ences in the protein’s in vivo and in vitro activity are
identified.
Materials and methods
Generation of mWisp3 cDNA Full-length mWisp3 cDNA
(Genbank accession number: XP_282903) was amplified
by RT-PCR using mouse testis cDNA and cloned into the
Not I and Xba I sites of pcDNA3.1 vector (Invitrogen).
Constructs were sequenced to verify that no PCR-induced
mutations had occurred and there was no difference
between the mWisp3 clone and the Genbank sequence.
Transient transfection of HEK293T cells with the mWisp3
expression vectors used to produce transgenic mice
HEK293T cells were grown in Dulbecco’s Minimum
Essential Medium (DMEM) (Invitrogen) supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin (PSM) (Invitrogen). Cells were maintained in
10 cm tissue culture plates (Falcon) at 37°C with 5% CO2
in a humidified incubator. HEK293T cells were transfected
at 70–80% confluency with 4 μg of empty expression
vector or vector containing mWisp3 cDNA using Lipofect-
Amine/Plus Reagent (Invitrogen) in 6.5 mL serum-free
DMEM. Four hours (h) after transfection, 6.5 mL of
DMEM supplemented with 20% FBS was added to the
cultures and allowed to incubate overnight. The medium
was then replaced with 10 mL of DMEM containing 10%
FBS for 24 h followed by 5 mL of serum-free DMEM for
24 h. Conditioned medium was then recovered and
centrifuged at 16,000 g for 5 min. One-hundred-twenty-
five μL of supernatant was then acetone precipitated (5:1
acetone:medium) overnight at −20°C followed by centrifu-
gation at 16,000 g for 5 min. Acetone was poured off and
the pellets were dried before re-suspension in 40 μL1 ×
sodium dodecyl sulfate (SDS) sample loading buffer at 55°C
for 10 min. Cell lysate was recovered by scraping following
incubation with 1 mL RIPA buffer (150 mM NaCl, 0.5%
deoxycholate, 1% NP-40, 0.1% SDS, and 50 mM Tris,
pH 8.0) for 5 min. Cell lysate was centrifuged at 16,000 g for
5 min to clear insoluble cellular debris. Equal volumes of
supernatant and 2 × SDS sample loading solution were then
mixed. β-mercaptoethanol was added to cell lysate and
conditioned medium samples (5% v/v) prior to boiling and
separation by SDS-PAGE.
Generation of mWisp3 transgenic mice The plasmid vector
pcDNA3.1, which drives transgene expression in multiple
tissues via a CMV promoter (Yu et al. 2005; Valverde et al.
2008), was used to produce one transgenic strain of mice
(CMV-WISP3). The pCAGGS vector, which drives trans-
gene expression using a chicken-β-actin promoter/CMV
enhancer (Niwa et al. 1991), was used to produce another
transgenic strain (β-actin-WISP3). Full-length mWisp3
cDNA was subcloned into the EcoRI site of pCAGGS
vector. Plasmid DNA was injected into the pronuclei of
B6-SJL/F2 oocytes and placed into pseudopregnant females
to produce transgenic offspring. Transgenic animals were
identified by Southern blot using tail DNA with a mWisp3
cDNA probe. Transgenic animals were then mated with
106 Y. Nakamura et al.129/SvEv wild-type mice to test for germline transmission
of the transgene.
Characterization of mWisp3 transgenic mice Mice were
maintained in a specific pathogen free facility and permitted
to age with their non-transgenic littermates. Mice were
inspected daily for phenotypic findings. Mice were sacri-
ficed and processed for RNA and protein extraction, primary
cell culture, and histologic examination at time points
ranging from embryonic day 14 (E14) to 62 weeks-of-age.
RT-PCR was performed using total RNA from fresh-
frozen tissue samples after extraction using Isogen
(Nippon Gene Co.) according to the manufacturer’si n s t r u c -
tions. RT-PCR product was subcloned and sequenced using
standard methods.
Histologic specimens were fixed in 10% buffered
formalin (Fisher) before being placed in Tissue-Tek biopsy
cassettes (Sakura Finetek). Samples were then processed
and embedded in paraffin. Five μm-thick tissue sections
were collected on Superfrost/Plus slides (Fisher). Images
were viewed on a Leica DMLB microscope (Leica Micro-
systems Inc.) and captured using a Spot Camera and
software (Diagnostics Instruments, Inc.).
For Western blotting, entire hearts, kidneys, or femoral
articular cartilages were immediately frozen in a methanol/
dry ice bath, homogenized in pestle tubes, and then
extracted on ice for 20 min in 1 mL Triton X-100 buffer
(20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 1% Triton
X-100, 1 mM EGTA, 10% Glycerol, 1.5 mM MgCl2, 1m M
dithiothreitol, 1 mM sodium vanadate, 50 mM sodium
fluoride, and proteinase inhibitor mixture (Roche)). The
protein concentrations were determined by Bradford Assay,
and the samples were stored at −80°C until use.
Primary kidney cell culture Four-week-old β-actin-WISP3
transgenic and non-transgenic littermates were sacrificed
and their kidneys were recovered. After three washes with
sterile PBS containing 10% PSM, the kidneys were minced
into small pieces and digested in 10 mL DMEM/F12
medium containing 1 mg/mL Collagenase A (Roche) and
10% BSA on a 10 cm dish at 37°C for 30 min in a tissue
culture incubator. Following gentle suspension using a
pipet, the mixture was passed through a cell strainer into a
50 mL Falcon tube and centrifuged at 1,000 g for 10 min.
The supernatant was discarded and the cell pellet was
suspended in 3 mL of fresh DMEM/F12 containing 20%
FCS and 1% PSM. From each transgenic and non-
transgenic kidney 1×10
7 cells/mL were plated onto 10 cm
tissue culture plates. The medium was changed daily for
2 days. Adherent cells were recovered by trypsin digestion,
re-plated, and grown to confluence in another 2 days.
Conditioned medium and cell lysate were then recovered,
as described above, and stored −80°C until use.
Immunodetection of WISP3 following SDS-PAGE Tissue
extract, conditioned medium, and cell lysate samples were
electrophoresed in 12% Tris-HCl gels (BioRad), transferred
to Immobilon P membrane (Millipore Corp.), and then
blocked with 4% dry milk in Tris-buffered saline (TBS) at
4°C overnight. Primary and secondary antibodies were
diluted using 4% dry milk/TBS with 0.05% Tween 20
(TBST). WISP3-C rabbit polyclonal antibody (Kutz et al.
2005; Nakamura et al. 2007) was used as the primary
antibody (1:500 dilution) and goat anti-rabbit HRP-
conjugated antibody (Pierce) was used as the secondary
antibody (1:5,000). ECL plus Western blotting Detection
System (Amersham Biosciences) and X-OMAT AR film
(Eastman Kodak Company) were used for developing blots
and detecting signal.
Generationofexpressionconstructsandin vitro transcription
of RNAs for injection into zebrafish embryos Full-length
zWisp3 cloned into the pCS2+ expression vector has been
described previously (Nakamura et al. 2007). Full-length
mWisp3 was also cloned into the pCS2+ vector. Other
cDNA constructs used in this study included human DKK1
(hDKK1) and zebrafish Wnt8 (zWnt8) (Nakamura et al.
2007). The RNAs were synthesized from Not I digested
pCS2+ plasmids using the sp6 mMessage mMachine kit
(Ambion). Phenol red (0.1%) was added to the RNA
solution as a tracer, and 150 pg of RNA was injected into 1
or 2-cell-stage embryos. Following injections, embryos
were cultured in aquatic system water. Phenotypic scoring
for evidence of BMP and Wnt inhibition were as previously
described (Nakamura et al. 2007).
Co-immunoprecipitation experiments COS7 cells were cul-
tured in DMEM supplemented with 10% FBS. Cells were
plated at 2×10
5 cells per well in six-well culture plates 24 h
prior to transfection. Cells were co-transfected with 2 μgo f
mBMP4-myc plasmid and 0.5 μg of mSPC4 plasmid
(Nakamura et al. 2007). Twenty-four h after transfection,
the culture medium was changed to1 mL OPTIMEM (Gibco-
BRL) containing 1% Knockout SR (Invitrogen). mBMP4-
myc-containing conditioned medium was collected 48 h later
and stored frozen at −80°C until use. Five-hundred μLo f
mBMP4-myc-containing conditioned medium was mixed
with either 1 mL of β-actin-WISP3-transgenic, or non-
transgenic, primary kidney cell culture conditioned medium
and 65 μL of anti-myc beads (Santa Cruz Biotechnology).
The samples were rocked overnight at 4°C. Beads were
pelleted, washed four times at 4°C for 5 min each in RIPA
buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% NP-40, 0.5%
deoxycholate, 0.1% SDS), then resuspended in 65 μL2×
SDS-PAGE loading buffer with 5% BME. After boiling for
5m i n ,2 0μL were separated by SDS-PAGE, transferred to
Immobilon P and immunodetected using HRP-conjugated
WISP3 over-expressing mice 107anti-myc antibody (Santa Cruz Biotechnology) and WISP3-C
antibody. Immunoreactive bands were detected as previously
described.
Bioassay for BMP signaling in mammalian cells BMP
signaling bioassays were performed using mouse
C3H/10T1/2 cells. Cells were plated in 96-well plates
(2×10
4 cells/well) and recombinant human BMP2 (rhBMP-2)
(R&D Systems) was added to the culture medium (final
concentration=100 ng/mL). Cells were then cultured in
50 μLo fD M E M( 1 0 %F B S )a n d5 0μLo fβ-actin-
WISP3-transgenic or non-transgenic primary kidney cell
conditioned medium. The culture medium was changed every
other day, until the cells were harvested on day 6. The cells
were washed twice with ice-cold PBS and alkaline phospha-
tase activity was measured with the LabAssay
TM ALP kit
(Wako Chemicals USA Inc.) according to the manufacturer’s
protocol. Total protein content was determined with the BCA
Protein Assay kit (Pierce Chemical Co.) using bovine
albumin as a standard. Results are expressed as units ALP
activity per microgram of total cell protein. Experiments were
performed in triplicate on two separate occasions.
Results
mWisp3 cDNA corresponding to wild-type sequence was
subcloned to produce pcDNA3.1 (CMV-WISP3) and
pCAGGS (β-actin-WISP3) expression vectors, which were
then used to transiently transfect HEK293T cells. The
constructs produced immunodetectable WISP3 in the condi-
tioned medium of HEK293T cells (Fig. 1). The constructs
were then used to produce transgenic mice.
Sixty-nine and 61 pronuclear injections were performed
using the CMV-WISP3 and β-actin-WISP3 constructs, and
8 (12%) and 10 (16%) transgenic offspring were recovered,
respectively. Two lines each for the CMV-WISP3 (lines 9
and 16) and β-actin-WISP3 (lines 37 and 38) transgenes
were maintained. Transgene copy numbers for these lines
ranged from 2 to 7 copies as determined by Southern blot
analysis (data not shown). Transgenic offspring were
obtained at the expected Mendelian ratios, consistent with
there being a single insertion site and no embryonic lethality.
For the CMV-WISP3 lines, 17 of 38 (line 9) and 6 of 12 (line
16) initial offspring were transgene positive. For β-actin-
WISP3 lines 14 of 29 (line 37) and 14 of 27 (line 38) initial
offspring were transgene positive. We were surprised by the
absence of a phenotype in the transgenic mice and by their
recovery at the expected Mendelian frequencies. Therefore,
we confirmed that the sequence of the mWisp3 transgenes in
these animals were wild-type by subcloning and sequencing
the full-length RT-PCR transcript.
We performed RT-PCR and detected mWisp3 transgene
expression at E14 and P1 in the heart and kidneys of beta-
actin-WISP3 mice (data not shown), but did not observe
immunodetectable WISP3 by Western blot at these time
points; however, WISP3 protein was clearly present by P7
and remained readily detectable until at least 52-weeks of
age. Failure to detect WISP3 protein prior to P7 could be
due to post-transcriptional regulation of Wisp3 mRNA,
which reduces its translation and consequent protein
Fig. 1 Detection of mWISP3 in transiently transfected cells and in
transgenic mice. a Immunoblots of whole protein extracts of cardiac
tissue recovered from β-actin-WISP3 transgenic mice at embryonic
day 14 (E14) and post-natal days 1 (P1) and 7 (P7), and postnatal
weeks 5 (P5W), 8 (P8W), 12 (P12W), and 52 (P52W). Extracts were
separated by 10% SDS-PAGE gel and immunodetected using anti-
WISP3-C antibody. Conditioned medium containing recombinant
mWISP3 expressed by HEK293T cells (mWISP3 CM) serves as
a positive control (arrow), whereas a cardiac tissue extract from a
52-week-old non-transgenic littermate (nonTG-P52W) serves as a
negative control. Note that mWISP3 protein is detected at P7 and at all
older ages in the transgenic animals and not in the non-transgenic
animal. Also note the presence of a C-terminal WISP3 cleavage
product (arrowhead) in the HEK293T conditioned medium and the
transgenic cardiac extracts. Immunodetection with an anti-tubulin
antibody serves as a loading control. b Immunoblots of whole protein
extracts of kidney tissue recovered from β-actin-WISP3 transgenic
mice separated by 10% SDS-PAGE gel and immunodetected using
anti-WISP3-C antibody. Conditioned medium containing recombinant
mWISP3expressedbyHEK293Tcells(mWISP3CM)servesasapositive
control (arrow) whereas kidney extractfroma 52-week-oldnon-transgenic
littermate (nonTG-P52W) serves as a negative control. Note that mWISP3
protein is detected at P7 and at all older ages in the transgenic animals and
not in the non-transgenic animal. Also note the presence of a C-terminal
WISP3 cleavage product (arrowhead) in the HEK293T conditioned
medium and the transgenic cardiac extracts. Immunodetection with an
anti-tubulin antibody serves as a loading control
108 Y. Nakamura et al.expressionduringembryonicandearlypostnataldevelopment,
or due to requirement for sufficient WISP3 protein to
accumulate in tissues before it becomes detectable with the
WISP3-C polyclonal antibody. We allowed CMV-WISP3 (N=
51) and β-actin-WISP3 (N=62) transgenic animals to age
along with comparable numbers of non-transgenic littermates
(N=48). Visual inspection of the transgenic mice for
abnormal behavior, activity, skeletal growth, health, and life
expectancy revealed no differences between the transgenics
and non-transgenics. The weights of the transgenic mice also
did not differ from those of their non-transgenic littermates
(male transgenic: 34.33±0.92 g, N=12; male non-transgenic:
35.28±1.3 g, N=12 at 9 months old; p>0.05). Despite clear
over-expression of WISP3 in kidney, heart, and cartilage, no
histologic differences were observed between the transgenic
and non-transgenic mice (Fig. 2a–c).
Because we found no phenotypic differences between
transgenic and non-transgenic littermates, but previously
found WISP3 to be biologically active when over-
expressed in zebrafish and in mammalian cell cultures in
vitro, we sought to determine whether WISP3 used in these
experiments differed from WISP3 expressed in the trans-
genic mice. COS7 and CHO cells are unable to efficiently
synthesize and secrete recombinant hWISP3 (Kutz et al.,
unpublished data), whereas HEK293T cells are able to
synthesize and secrete hWISP3 and mWISP3. The apparent
molecular weight of HEK293T cell-expressed mWISP3
appears larger than the mWISP3 recovered from transgenic
tissue (Fig. 1), but does not substantially differ in size from
that recovered from the transgenic primary kidney cell
cultures (Fig. 2d). However, we cannot exclude differences
in post-translational modifications between WISP3
expressed by HEK293T and expressed by primary kidney
cells, since the size of the protein in the conditioned
medium is larger than that still undergoing synthesis within
the cells (Fig. 2d). Interestingly, the WISP3 C-terminal
cleavage fragment observed in medium from HEK293T
cells and primary kidney cells (Fig. 2d) was also observed
in the transgenic tissue extracts (Fig. 1a, b), indicating that
human and mouse cells have the ability to perform this
cleavage event. However, we do not yet know whether this
cleavage event is biologically significant, since the WISP3
over-expressing mice did not develop a phenotype.
We previously reported that zWISP3 over-expression
inhibited BMP and Wnt signaling in zebrafish (Nakamura
et al. 2007). The absence of a phenotype in the transgenic
mice led us to question whether mWISP3 has this biologic
activity. We injected mWisp3 RNA into fertilized zebrafish
oocytes. mWISP3 was able to inhibit BMP signaling in
zebrafish, although it was less efficient at doing so than
zWISP3 (Fig. 3a). However, unlike zWISP3, which
inhibited zWnt8a signaling in zebrafish, mWISP3 had no
Wnt inhibitory effect in the zebrafish assay (Fig. 3b). We
next studied the in vitro biologic properties of mWISP3
produced by the primary kidney cell cultures from
transgenic mice. Co-immunoprecipitation experiments
revealed that mWISP3 in primary kidney cell culture
conditioned medium could physically interact with mBMP4
(Fig. 3c). To test whether mWISP3 could inhibit BMP
signaling we added recombinant human BMP2 (rhBMP2)
to mouse C3H/10T1/2 cells, cultured the cells in primary
kidney cell conditioned medium from transgenic, or non-
transgenic mice, and looked for a BMP-induced increase in
alkaline phosphatase (ALP) activity. Consistent with
hWISP3 and zWISP3 having BMP inhibitory activity
(Nakamura et al. 2007), conditioned medium from the
transgenic kidney cells, but not conditioned medium from
the non-transgenic kidney cells, was able to inhibit the
BMP2-induced increase in ALP activity (Fig. 3d). These
results indicate that mWISP3 protein expressed by the
transgenic mice has biologic activity in this in vitro assay.
Discussion
We created two strains of transgenic mice that over-express
mWisp3 mRNA and mWISP3 protein driven by the CMVor
β-actin promoters; these promoters drive broad and strong
expression of transgenes (Niwa et al. 1991; Yu et al. 2005;
Valverde et al. 2008). Surprisingly, mWisp3 transgenic mice
were phenotypically indistinguishable from their non-
transgenic littermates (Fig. 2). This result was unexpected
since we, and other investigators, have identified biologic
activities for WISP3 in several different systems (Kleer et
al. 2002; Kleer et al. 2004a; Kleer et al. 2004b; Sen et al.
2004; Kutz et al. 2005; Nakamura et al. 2007). Further-
more, we had assumed the low endogenous expression of
this protein was an indication of its biologic potency.
In contrast to WISP3, whose deficiency causes the
recessive disease PPD in humans and no phenotype in
mice, Cyr61-null mice do not survive due to defects in
placentation and large blood vessel formation (Mo et al.
2002). CTGF-null mice have a neonatal lethal skeletal
dysplasia (Ivkovic et al. 2003) involving endochondral and
intramembranous bone growth (Kawaki et al. 2008). Nov-
mutant mice are viable and fertile, but develop cataracts and
exhibit skeletal muscle and cardiac problems, including
cardiomyopathy and muscle atrophy (Heath et al. 2008).
WISP1 and WISP2 mutant mice have not yet been
reported; however, to date, no human genetic diseases have
been attributed to these genes. Therefore, the precise
biologic activities for the CCN family members have not
been clearly defined in vivo, although several activities
have been suggested from the in vivo and in vitro experi-
ments (Rachfal and Brigstock 2005; Canalis 2007; Kubota
and Takigawa 2007). Despite retaining conserved structural
WISP3 over-expressing mice 109motifs, the biologic pathways in which these proteins
function may have diverged. CTGF has been over-
expressed in mice using a Col11a2 promoter; these
transgenic mice developed postnatal onset dwarfism, low
bone mass, reduced fertility, and small testis (Nakanishi et
al. 2001). Interestingly, the CTGF over-expression pheno-
type involved tissues in which the Col11a2 driver was not
thought to be active. However, the mechanism by which the
phenotypes developed was not explored (Nakanishi et al.
2001). We previously produced mice that over-expressed
hWISP3 under the control of Col2a1 promoter-enhancer;
these mice were phenotypically normal (Kutz et al. 2005),
prompting us to create the mWisp3 transgenics that over-
express mWISP3 more broadly, which we describe herein.
Fig. 2 No histologic difference between Wisp3 knockout, Wisp3
transgenic, and non-transgenic mice. a Photomicrographs of hematoxylin
and eosin (H and E) stained sections of kidneys (10× and 40×
magnification) and hearts (5× and 40× magnification) recovered from
2.5-month-old (2.5 m.o.) knockout (KO), CMV-WISP3 transgenic
(CMV) and β-actin-WISP3 transgenic (β-actin), and non-transgenic
(non-TG) mice revealing no histologic differences between the strains. b
Photomicrographs of H and E stained sections of kidney and hearts
recovered from a 1.2-year-old (1.2 y.o.) CMV-WISP3 transgenic mouse
and its non-transgenic littermate. c Photomicrographs of sagittal sections
through the femoral-tibial joints recovered from a 4-month-old (4 m.o.)
β-actin-WISP3 mouse and its non-transgenic littermate. d Immunoblot of
mWISP3 in cell lysate (CL) and conditioned medium (CM) from
transiently transfected HEK293T cells and primary kidney cell cultures
from transgenic mice (TG-kidney) and non-transgenic littermates (non-
TG-kidney). Samples were separated by 12% SDS-PAGE under reducing
conditions and probed with the WISP3-C antibody. Intact mWISP3
(arrow) and the WISP3 C-terminal cleavage fragment (arrowhead) are
detected. Note that the difference in apparent molecular weight between
WISP3 in conditioned medium and in cell lysate is consistent with post-
translational modification. The extent of this modification is similar for
mWISP3 expressed by HEK293T cells and by primary kidney cells
110 Y. Nakamura et al.We excluded several causes for the lack of a phenotype in
the mWISP3 over-expressing mice. We subcloned and
sequenced the transgene mRNA transcript and confirmed it
had not mutated during transgenesis. We performed Western
blots on protein extracts from tissues where the CMVand β-
actin promoters are known to be active and confirmed that
immunodetectable mWISP3 was produced (Fig. 1a, b). We
injected mWisp3 RNA into zebrafish embryos and observed
a phenotype consistent with BMP inhibition (Fig. 3a).
Another CCN family member, Ctgf, has also been shown to
inhibit BMP signaling (Abreu et al. 2002), suggesting that
this biologic activity can be conserved within the CCN
family. We also tested mWISP3-containing conditioned
medium produced by transgenic mouse primary kidney cell
cultures and found that the mWISP3 could physically bind
BMP and inhibit BMP signaling in mammalian C3H10T1/2
cells (Fig. 3c, d).
The lack of a phenotype in mice over-expressing WISP3
contrasts with the striking phenotypes occurring in transgenic
mice that over-express the BMP inhibitor Noggin. Podocyte-
specificover-expression caused massive mesangial expansion
in kidneys (Miyazaki et al. 2006). Osteoblast-specific over-
expression of Noggin caused reduced bone mass and skeletal
fragility (Devlin et al. 2003). Follciular over-expression
of Noggin caused hair loss (Kulessa et al. 2000)a n d
intestinal over-expression caused ectopic villus crypt
Fig. 3 mWISP3 inhibits BMP signaling in zebrafish embryos and in
mammalian cells. a Graph depicting the frequency of the phenotypic
outcomes following the injection of zWisp3, mWisp3, or GFP RNA
into zebrafish embryos. Embryos classified as “mild” consequences of
BMP inhibition correspond to convergence-extension classes, C1 and
C2, “medium” to C3 and C4, and “severe” to C5 as reported in
(Kishimoto et al. 1997). Note that GFP RNA (negative control) had
no effect, and that zWisp3 was a more potent inhibitor in this assay
than mWisp3. b Graph depicting phenotype frequencies caused by
injection of zWnt8 RNA alone, zWnt8 with hDKK1 RNA, zWisp3
RNA, or mWisp3 RNA. Note that zWnt8 injection causes rostral
deformities (death, absent head, small eyes) that are substantially
rescued by co-injection of the Wnt inhibitor hDKK1. The zWnt8
phenotype was also inhibited by co-injection of zWisp3, but not by
mWisp3. c Immunoblot following co-immunoprecipitation. COS7 cell
conditioned medium containing myc-tagged mBMP4 (mBMP4-myc)
was mixed with conditioned medium recovered from primary kidney
cell cultures from β-actin-WISP3 transgenic mice. Following immu-
noprecipitation with anti-myc antibody, proteins were separated by
12% SDS-PAGE under reducing conditions and probed with anti-myc
antibody (upper panel) and anti-WISP3-C antibody (lower panel).
Note that mBMP4 was able to physically interact and co-precipitate
intact mWISP3, but not the WISP3 C-terminal cleavage fragment
(bottom panel). d Graph depicting the alkaline phosphatase (ALP)
activity in C3H/10T1/2 cells cultured with recombinant human BMP2
(rhBMP2). Note rhBMP2 (100 ng/mL) induces ALP activity and that
this induction is reduced when cells were cultured in conditioned
medium recovered from primary kidney cell cultures from β-actin-
WISP3 transgenic mice compared to conditioned medium recovered
from primary kidney cell cultures from non-transgenic mice
WISP3 over-expressing mice 111formation (Haramis et al. 2004). We cannot explain why
biologic activities for WISP3 can be demonstrated in
cultured cells and in zebrafish, but not in live mice. It is
possible that the in vivo activity of WISP3 may be tightly
regulated by components within tissues that are absent in
cell cultures where protein may be released into medium.
An alternative possibility is that evolutionary divergence
has led to WISP3 becoming non-functional in mice.
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